Patient Care Costs in Cancer Clinical Trials

Publication
Article
OncologyONCOLOGY Vol 15 No 6
Volume 15
Issue 6

Rep. Pryce is also cochair of the House Cancer Working Group. In March, she introduced the Access to Cancer Clinical Trials Act (H.R. 967), which would require health insurers to pay for the routine costs incurred by patients in

Rep. Pryce is also cochair of the House Cancer Working Group. InMarch, she introduced the Access to Cancer Clinical Trials Act(H.R. 967), which would require health insurers to pay for the routine costsincurred by patients in cancer clinical trials. This would be a further step infederal policy beyond the Clinton administration’s national coverage decisionthat went into effect in September 2000. The Pryce bill calls for coverage ofall participants in cancer clinical trials, regardless of age, including thoseconducted by nonfederal research entities—a category of trials not included inthe Clinton policy.

Recent Videos
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
2 experts are featured in this series.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
2 experts are featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Related Content